Chris Viehbacher

Chairman of the Board of Directors

Chris Viehbacher is the Managing Partner of Gurnet Point Capital. Gurnet Point is a Boston-based investment fund associated with the Bertarelli family and has a $ 2 billion capital allocation. He is also a member of the Board of Pure Tech Health plc and is the Chairman of Vedanta. He is a member of the Board of Trustees of Northeastern University.

Chris is the former CEO and Member of the Board of Directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris. He was also the Chairman of the Board of Genzyme in Boston.

Prior to joining Sanofi, Chris spent 20 years with GlaxoSmithKline in Germany, Canada, France and the US as President of GSK North America. He was a Member of the Board of Directors of GSK Chris has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide. He has also received France's highest civilian honor, the Legion d'Honneur.

Bernat Olle, Ph.D.

Chief Executive Officer

Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of several companies of the PureTech portfolio and served as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences.

In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in the Republic of Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.

Ending the War on Microbes | Bernat Olle | TEDxCambridge

Ben Shapiro, M.D.

Board Member

Dr. Shapiro is a co-founder and Non-Executive Director of PureTech Health. He was previously Executive Vice President of Research for Merck. In this position he was responsible for all basic and preclinical research activities at Merck worldwide. Dr. Shapiro led the research program that resulted in FDA registration of approximately 25 drugs and vaccines. In addition to overseeing Merck internal research, Dr. Shapiro was responsible for in-licensing activities. Previously, he was Professor and Chairman of the Department of Biochemistry at the University of Washington.

Dr. Shapiro is the author of over 120 papers on the molecular regulation of cellular behavior and the biochemical events that integrate the cascade of cellular activations at fertilization. He has served on many institutional advisory boards and scientific review panels, and has been a member of the board of various life science companies, including Momenta, Celera and Ikaria. He also sits on the boards of PureTech Health, the Drugs for Neglected Disease Initiative and the Mind and Life Institute. Dr. Shapiro received his M.D. from Jefferson Medical College.

John LaMattina, Ph.D.

Board Member

Dr. LaMattina is a Non-Executive Director at PureTech Health. He was previously President, Pfizer Global Research and Development and Senior Vice President, Pfizer Inc., a company where he had a 30-year career. During Dr. LaMattina's leadership tenure, Pfizer discovered and/or developed a number of important new medicines including Tarceva, Chantix, Zoloft (PTSD), Selzentry and Lyrica, along with a number of other medicines currently in late stage development for cancer, rheumatoid arthritis and pain.

Dr. LaMattina is the author of numerous scientific publications and U.S. patents. He is also the author of Drug Truths: Dispelling the Myths About Pharma R&D, and Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image?. Dr. LaMattina received the 1998 Boston College Alumni Award of Excellence in Science, the 2004 American Diabetes Association Award for Leadership and Commitment in the Fight Against Diabetes, an Honorary Doctor of Science degree from the University of New Hampshire, the Just One Break, Inc. Lifetime Achievement Award, the Legal Momentum Equal Opportunity Award, and the American Chemical Society's Earle B. Barnes Award for Leadership in Chemical Research Management. He is a member of the Board of Trustees of Boston College. Dr. LaMattina received a Ph.D. in Organic Chemistry from the University of New Hampshire.

David Steinberg

Co-Founder, Board Member

David Steinberg is the Chief Innovation Officer at PureTech Health. As a member of PureTech Health, Mr. Steinberg has led the development of a number of programs, including Vedanta Biosciences, Entrega Biosciences, Vor Biopharma, and Commense Health. He is a co-founder of resTORbio and also served as Chief Business Officer of Follica, Inc.

Previously, Mr. Steinberg was a strategy consultant with the Boston Consulting Group and Vertex Partners, focusing on R&D and product strategy and strategic alliances for Fortune 500 pharmaceutical and biotechnology clients.

Mr. Steinberg also worked as a research associate in Procter and Gamble Pharmaceuticals' R&D organization. He received his BA in Biology with distinction from Cornell University and graduated with high honors from the University of Chicago Booth School of Business with an MBA in Strategy and Finance. Mr. Steinberg is also a member of the UChicago Tech Innovation Fund Advisory Committee.